AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19506377 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsafe injecting practices (sharing filters)
Number of subjects: 446
Study 19506377 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsafe injecting practices (syringe‐mediated drug sharing)
Number of subjects: 446
Study 19506377 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of unsafe injecting (urban environmental characteristics)
Number of subjects: 446
Study 19506377 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of unsafe injecting (social norms)
Number of subjects: 446
Study 19506377 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of unsafe injecting (cleaning used syringes)
Number of subjects: 446
Study 19506377 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of unsafe injecting (self‐report of HIV infection)
Number of subjects: 446
Study 16884321 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT administered as four 100 microg tablets simultaneously
Number of subjects: 27
Study 16884321 — intervention group
Group type: COMPARATOR
Intervention: FBT administered as one 400 microg tablet
Number of subjects: 27
Study 16884321 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial sampling
Number of subjects: 27
Study 16884321 — intervention group
Group type: COMPARATOR
Intervention: Venous sampling
Number of subjects: 27
Study 16004743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissemination of full guidelines
Number of subjects: 0
Study 16004743 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritised review criteria
Number of subjects: 0
Study 16004743 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria plus feedback
Number of subjects: 0
Study 16004743 — intervention group
Group type: COMPARATOR
Intervention: Control (other interventions)
Number of subjects: 0
Study 12858158 — intervention group
Group type: EXPERIMENTAL
Intervention: Imprint cytology
Number of subjects: 38
Study 12858158 — intervention group
Group type: COMPARATOR
Intervention: Frozen-section biopsy (FSB)
Number of subjects: 38
Study 9927370 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm of NO2 for 4 h on four consecutive days
Number of subjects: 0
Study 7571476 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg or 8 mg administered once a day)
Number of subjects: 31
Study 7571476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of perindopril with hydrochlorothiazide
Number of subjects: 31
Study 7571476 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (monotherapy and combination)
Number of subjects: 31
Study 7571476 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 31
Study 2153736 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 15% idoxuridine in dimethyl sulfoxide
Number of subjects: 301
Study 2153736 — intervention group
Group type: COMPARATOR
Intervention: 80% DMSO control solution
Number of subjects: 301
Study 2153736 — intervention group
Group type: COMPARATOR
Intervention: 2% DMSO control solution
Number of subjects: 301
Study 6792978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactinex
Number of subjects: 48
Study 6792978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30326318 — intervention group
Group type: EXPERIMENTAL
Intervention: Biographical suspension concept
Number of subjects: 20
Study 30326318 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom resolution
Number of subjects: 20
Study 30326318 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspended liminality
Number of subjects: 20
Study 30326318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing symptoms
Number of subjects: 20
Study 30326318 — intervention group
Group type: EXPERIMENTAL
Intervention: State of being between sickness and wellness
Number of subjects: 20
Study 27974224 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped (DVD) parenting skills intervention
Number of subjects: 60
Study 27974224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 27974224 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 60
Study 25727393 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke available in 24 hours
Number of subjects: 90
Study 25727393 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke available in 3 hours
Number of subjects: 90
Study 25727393 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke available in 20 minutes
Number of subjects: 90
Study 25727393 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported urge
Number of subjects: 90
Study 22831752 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocortical locking plate (group A; n = 28)
Number of subjects: 55
Study 22831752 — intervention group
Group type: COMPARATOR
Intervention: Bicortical screw (group B; n = 27)
Number of subjects: 55
Study 21036514 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient setting
Number of subjects: 68
Study 21036514 — intervention group
Group type: COMPARATOR
Intervention: Outpatient setting
Number of subjects: 68
Study 21036514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both settings
Number of subjects: 68
Study 18319227 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-propionyl-carnitine (LPC) during supervised physical training
Number of subjects: 0
Study 18319227 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training
Number of subjects: 0
Study 18319227 — intervention group
Group type: EXPERIMENTAL
Intervention: LPC infusions
Number of subjects: 0
Study 17000941 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medical record reminder
Number of subjects: 961
Study 17000941 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated voice message
Number of subjects: 961
Study 17000941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy team outreach
Number of subjects: 961
Study 17000941 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 961
Study 14520243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclosure of peritoneum
Number of subjects: 0
Study 14520243 — intervention group
Group type: COMPARATOR
Intervention: Closure of peritoneum
Number of subjects: 0
Study 10743823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (200-400 mg/day)
Number of subjects: 380
Study 10743823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 10743823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 380
Study 8937605 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (20 micrograms infused over one-half hour)
Number of subjects: 20
Study 8937605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DDAVP)
Number of subjects: 20
Study 1458526 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneously applied collagen (group A; n = 50)
Number of subjects: 100
Study 1458526 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressure dressing (group B; n = 50)
Number of subjects: 100
Study 6487462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosidimine 2.5 mg
Number of subjects: 5
Study 6487462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosidimine 5.0 mg
Number of subjects: 5
Study 6487462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosidimine 7.5 mg
Number of subjects: 5
Study 6487462 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 5
Study 29599038 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-related preoperative education
Number of subjects: 140
Study 29599038 — intervention group
Group type: COMPARATOR
Intervention: Control group (no opioid-related preoperative education)
Number of subjects: 140
Study 26653112 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU daily vitamin D3
Number of subjects: 38
Study 26653112 — intervention group
Group type: COMPARATOR
Intervention: 400 IU daily vitamin D3
Number of subjects: 38
Study 25347898 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 0
Study 25347898 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate (conventional chemotherapy)
Number of subjects: 0
Study 22925288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (SH) solution (0.2% two-fold diluted MucoUp)
Number of subjects: 94
Study 22925288 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 94
Study 20818887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg subcutaneous)
Number of subjects: 72
Study 20818887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 18477422 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (MICA)
Number of subjects: 0
Study 18477422 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L‐AMB)
Number of subjects: 0
Study 15807739 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (1 mg/kg/day) + Vitamin E (800 IU/day)
Number of subjects: 82
Study 15807739 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin (1 mg/kg/day)
Number of subjects: 82
Study 14556129 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg epinephrine with 1.5% lidocaine
Number of subjects: 60
Study 14556129 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg epinephrine with 1.5% lidocaine
Number of subjects: 60
Study 14556129 — intervention group
Group type: COMPARATOR
Intervention: 1.5% lidocaine alone
Number of subjects: 60
Study 12370843 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina oil
Number of subjects: 68
Study 12370843 — intervention group
Group type: COMPARATOR
Intervention: Rapeseed oil
Number of subjects: 68
Study 12370843 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 68
Study 10426708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsupplemented formula
Number of subjects: 83
Study 10426708 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 83
Study 10426708 — intervention group
Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 83
Study 7485885 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 100 mg
Number of subjects: 40
Study 7485885 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac 10 mg
Number of subjects: 40
Study 2181312 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ivermectin (21.3 +/- 0.7 micrograms per kilogram; n = 13)
Number of subjects: 40
Study 2181312 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ivermectin (126.2 +/- 3.7 micrograms per kilogram; n = 13)
Number of subjects: 40
Study 2181312 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine (6 mg per kilogram per day for 12 days preceded by 3 mg per kilogram for 1 day; n = 14)
Number of subjects: 40
Study 7029369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 69
Study 7029369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31624364 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematologic biomarkers (Hemoglobin)
Number of subjects: 2100
Study 31624364 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematologic biomarkers (Hepcidin)
Number of subjects: 2100
Study 31624364 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin cutoff <4.3 µg/L
Number of subjects: 2100
Study 31624364 — intervention group
Group type: COMPARATOR
Intervention: Baseline hemoglobin >110 g/L
Number of subjects: 2100
Study 31624364 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hepcidin >1.6 µg/L
Number of subjects: 2100
Study 31120390 — intervention group
Group type: EXPERIMENTAL
Intervention: Early morphosyntactic knowledge
Number of subjects: 714
Study 31120390 — intervention group
Group type: EXPERIMENTAL
Intervention: Early comprehension of relational terms
Number of subjects: 714
Study 28108117 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticidal bait
Number of subjects: 102
Study 28108117 — intervention group
Group type: COMPARATOR
Intervention: Control homes
Number of subjects: 102
Study 26425700 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma DNA methylation profiles
Number of subjects: 204
Study 23305245 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim 200 mg twice daily from day 5 to 10
Number of subjects: 24
Study 21557754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandy™ (959 ppm F, tutti-frutti-flavored)
Number of subjects: 155
Study 21557754 — intervention group
Group type: COMPARATOR
Intervention: Sorriso™ (1219 ppm F, peppermint-flavored)
Number of subjects: 155
Study 21557754 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g of dentifrice
Number of subjects: 155
Study 21557754 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g of dentifrice
Number of subjects: 155
Study 18461392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of 0.1 ml 1% acetylcholine in group A
Number of subjects: 30
Study 18461392 — intervention group
Group type: COMPARATOR
Intervention: Surgery in group B (1999-2001)
Number of subjects: 30
Study 17519054 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing
Number of subjects: 113
Study 15167456 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 2334
Study 15167456 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 2334
Study 11282810 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of paroxetine
Number of subjects: 230
Study 11282810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 11282810 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual reduction of diazepam
Number of subjects: 230
Study 11282810 — intervention group
Group type: EXPERIMENTAL
Intervention: Total group
Number of subjects: 230
Study 9754775 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg plus Amoxicillin 1000 mg b.i.d (OA)
Number of subjects: 28
Study 9754775 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg and Placebo b.i.d (OP)
Number of subjects: 28
Study 7826832 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) - total dose of 1500 mg given over 3 days
Number of subjects: 14
Study 7826832 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 14
Study 7826832 — intervention group
Group type: EXPERIMENTAL
Intervention: Desethylchloroquine (DECQ)
Number of subjects: 14
Study 7826832 — intervention group
Group type: EXPERIMENTAL
Intervention: DECQ to CQ ratio
Number of subjects: 14
Study 2900013 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (2 months)
Number of subjects: 21
Study 2900013 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (2 months)
Number of subjects: 21
Study 29446268 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized trays (TB)
Number of subjects: 50
Study 29446268 — intervention group
Group type: COMPARATOR
Intervention: Strips (SB)
Number of subjects: 50
Study 29446268 — intervention group
Group type: EXPERIMENTAL
Intervention: Trays (TB)
Number of subjects: 50
Study 27561870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics Web‐based intervention
Number of subjects: 41
Study 27561870 — intervention group
Group type: COMPARATOR
Intervention: 1‐800‐QUIT‐NOW telephone line
Number of subjects: 41
Study 24966150 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-epidural anaesthesia (PEA)
Number of subjects: 40
Study 24966150 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 40
Study 22882208 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 applications of 0.15-mm microneedles
Number of subjects: 0
Study 22882208 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 applications of 0.25-mm microneedles
Number of subjects: 0
Study 22882208 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 applications of 0.15-mm microneedles
Number of subjects: 0
Study 22882208 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 applications of 0.25-mm microneedles
Number of subjects: 0
Study 21235066 — intervention group
Group type: COMPARATOR
Intervention: EA-proximal acupoints group (EA-PA group)
Number of subjects: 120
Study 21235066 — intervention group
Group type: COMPARATOR
Intervention: EA-distant acupoints group (EA-DA group)
Number of subjects: 120
Study 21235066 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) group
Number of subjects: 120
Study 18454214 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg.kg-1 ketamine 5%
Number of subjects: 100
Study 18454214 — intervention group
Group type: COMPARATOR
Intervention: 2.5% ketamine
Number of subjects: 100
Study 16418156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve gliding exercises combined with conservative treatment
Number of subjects: 26
Study 16418156 — intervention group
Group type: COMPARATOR
Intervention: Static volar wrist splints and conservative treatment
Number of subjects: 26
Study 14736584 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer present (n=34)
Number of subjects: 64
Study 14736584 — intervention group
Group type: COMPARATOR
Intervention: Participant alone (n=30)
Number of subjects: 64
Study 11127075 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visit (20 minutes)
Number of subjects: 157
Study 11127075 — intervention group
Group type: COMPARATOR
Intervention: Unrelated topic intervention (control group)
Number of subjects: 157
Study 9369411 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate oxidase (Uricozyme)
Number of subjects: 134
Study 9369411 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 134
Study 1607432 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable preparation containing chlorhexidine
Number of subjects: 0
Study 1607432 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 0
Study 1607432 — intervention group
Group type: COMPARATOR
Intervention: Xylitol control tablets
Number of subjects: 0
Study 3984878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (STK)
Number of subjects: 44
Study 3984878 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 44
Study 3984878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (STK) in patients with reperfusion
Number of subjects: 44
Study 3984878 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment) in patients with reperfusion
Number of subjects: 44
Study 2451713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy followed by definitive treatment (arm A)
Number of subjects: 116
Study 2451713 — intervention group
Group type: COMPARATOR
Intervention: Alternating chemotherapy and radiotherapy (arm B)
Number of subjects: 116
Study 31092666 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (structured exercise training, aerobic and resistance) supervised by a physiotherapist, 2 sessions/week for 6-10 weeks before surgery.
Number of subjects: 164
Study 31092666 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no prehabilitation).
Number of subjects: 164
Study 31092666 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (structured exercise training).
Number of subjects: 164
Study 28768654 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40-45% fat, 15% protein, 40-45% carbohydrate)
Number of subjects: 757
Study 28768654 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20-25% fat, 15% protein, 60-65% carbohydrate)
Number of subjects: 757
Study 28768654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 757
Study 24584605 — intervention group
Group type: EXPERIMENTAL
Intervention: MgCaCO3 (100 mg calcium, 85 mg magnesium per tablet)
Number of subjects: 20
Study 24584605 — intervention group
Group type: COMPARATOR
Intervention: CaCO3 (200 mg calcium per tablet)
Number of subjects: 20
Study 24379009 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef lunch (3-oz, 3 times weekly for 16 weeks)
Number of subjects: 43
Study 24379009 — intervention group
Group type: COMPARATOR
Intervention: Non-beef lunch (3-oz, 3 times weekly for 16 weeks)
Number of subjects: 43
Study 21257028 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleable protein matrix (MPM) 2 × 15 g/d
Number of subjects: 161
Study 21257028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 18790543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfotanshinone Sodium Injection (SSI) 60 mg combined with a loading dose of 300 mg aspirin and a maintenance dose of 100 mg of aspirin plus baseline therapy
Number of subjects: 100
Study 18790543 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg loading dose and 100 mg maintenance dose) plus baseline therapy
Number of subjects: 100
Study 16446121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin as add-on therapy
Number of subjects: 5
Study 12232545 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 5 mg
Number of subjects: 28
Study 12232545 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 100 mg
Number of subjects: 28
Study 12232545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of agomelatine
Number of subjects: 28
Study 12232545 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo run-in)
Number of subjects: 28
Study 9950657 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated protein C (APC) response
Number of subjects: 826
Study 7761292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of behavior modification and mutual goal setting
Number of subjects: 79
Study 7761292 — intervention group
Group type: COMPARATOR
Intervention: Mutual goal setting only
Number of subjects: 79
Study 7761292 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 79
Study 2175584 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg perindopril
Number of subjects: 6
Study 2175584 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg perindopril
Number of subjects: 6
Study 2175584 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg perindopril
Number of subjects: 6
Study 2175584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 373990 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.5 mg twice daily
Number of subjects: 60
Study 373990 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 2 mg three times daily
Number of subjects: 60